Technical Articles

tumor targeting
IGF1R 单抗的临床波折：从 figitumumab 单药到联合治疗范式转向
Clinical Setbacks of IGF1R Antibodies: From Figitumumab Monotherapy to a Combination-Treatment Paradigm Shift
发布时间 2026-10-08
After figitumumab monotherapy failed, the IGF1R antibody field shifted toward combination treatment and biomarker stratification. This article traces the paradigm shift in IGF1R translational research and its in vitro tool support.
View details
  • Cancer
  • IGF1R antibodies
  • figitumumab
  • ganitumab
  • combination therapy
  • biomarkers
  • tumor targeting
  • UA016082
  • alpha2beta2
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsCalculator ToolsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.